Marengo Therapeutics Teams Up with Gilead for a Clinical Trial
Marengo Therapeutics, Inc., an innovative biotech company in its clinical stage, has recently announced an exciting collaboration with Gilead Sciences, Inc. This partnership is set to investigate the combination of STAR0602 (Invikafusp alfa) and Trodelvy in a new clinical study designed for patients with metastatic breast cancer. The focus is particularly on those fighting triple-negative breast cancer (TNBC) as well as hormone receptor-positive, HER2-negative cancers.
Details of the Clinical Collaboration
This collaboration aims to evaluate STAR0602, which is a first-in-class T cell receptor (TCR) V? selective dual T cell agonist, alongside Gilead's Trodelvy, a Trop-2 directed antibody-drug conjugate (ADC). The clinical trial will be multi-center and is referred to as the START-002 Phase I/II study.
Groundbreaking Dual Action Method
In the upcoming study, Marengo Therapeutics will take the lead on the sponsorship, while Gilead will provide Trodelvy. STAR0602 has already demonstrated significant single-agent activity in various tumors resistant to PD-1 treatment in the ongoing START-001 Phase 1/2 trial, where it is being evaluated against advanced antigen-rich solid tumors on its own.
Striving for Improved Patient Outcomes
Dr. Kevin Chin, the Chief Medical Officer at Marengo, expressed his excitement about the prospects of combining STAR0602 with Trodelvy. He emphasized the distinct properties of both treatments, suggesting that their joint use could lead to more effective cancer elimination. This therapy aims to deliver cytotoxic agents directly to tumor locations, bolstering the formation of immune memory against cancer cells.
What to Expect from the Clinical Trial
The upcoming combination trial is set to start soon, with the goal of thoroughly assessing the safety, tolerability, and preliminary effectiveness of these two therapies working in concert. The primary aim is to identify potential new treatment options for those facing advanced types of breast cancer.
Regulatory Status and Future Prospects
It’s crucial to note that both STAR0602 and Trodelvy are investigational products and have not yet received approval from health authorities around the world. As such, the safety and efficacy of their combination remain unverified. Nonetheless, this joint trial could produce important insights that might change treatment protocols for patients with few options available.
About Marengo Therapeutics
Marengo Therapeutics is dedicated to developing groundbreaking treatments through its advanced STAR platform. This platform utilizes T cell-targeting antibodies tailored to selectively influence the T cell subsets that are vital in the fight against cancer. Their experienced team of experts in immunology and oncology is committed to improving patient health outcomes with innovative therapies.
More on STAR Platforms
The STAR™ Platform is Marengo’s proprietary technology that integrates various unique antibody-fusion elements. Its focus on germline encoded variable (V)? regions of the TCR is designed to effectively stimulate T cells while encouraging strong anti-tumor responses.
Frequently Asked Questions
What is the purpose of the collaboration between Marengo and Gilead?
The collaboration aims to evaluate the effectiveness of STAR0602 in combination with Trodelvy for treating metastatic breast cancers, specifically TNBC and HR+/HER2- types.
What does STAR0602 aim to achieve in cancer treatment?
STAR0602 seeks to selectively enhance T cell responses to target and eliminate cancer cells, improving overall patient outcomes.
What is Trodelvy used for?
Trodelvy is an antibody-drug conjugate primarily employed for treating metastatic breast cancers and is provided by Gilead for this clinical trial.
Are these treatments FDA approved?
Both therapies are currently investigational and have not received global health authority approval.
How can patients get involved in these studies?
Patients interested in the trial should reach out to their healthcare providers for information on enrollment opportunities.
